Imugene Limited (IUGNF)
USD 0.02
(-23.91%)
USD 0.02
(-23.91%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 151.39 Million AUD | -23.17% |
| 2023 | 197.06 Million AUD | 33.51% |
| 2022 | 147.6 Million AUD | 105.55% |
| 2021 | 71.8 Million AUD | 10.13% |
| 2020 | 65.2 Million AUD | 111.85% |
| 2019 | 30.77 Million AUD | 81.97% |
| 2018 | 16.91 Million AUD | 33.42% |
| 2017 | 12.67 Million AUD | 32.95% |
| 2016 | 9.53 Million AUD | 4.62% |
| 2015 | 9.11 Million AUD | 5.6% |
| 2014 | 8.63 Million AUD | 233.97% |
| 2013 | 2.58 Million AUD | 96.03% |
| 2012 | 1.31 Million AUD | -71.87% |
| 2011 | 4.68 Million AUD | 14.36% |
| 2010 | 4.09 Million AUD | -28.88% |
| 2009 | 5.76 Million AUD | 11.61% |
| 2008 | 5.16 Million AUD | -1.84% |
| 2007 | 5.26 Million AUD | -27.63% |
| 2006 | 7.26 Million AUD | -19.81% |
| 2005 | 9.06 Million AUD | 50.67% |
| 2004 | 6.01 Million AUD | -26.13% |
| 2003 | 8.14 Million AUD | 864.49% |
| 2002 | 844.39 Thousand AUD | -65.4% |
| 2001 | 2.44 Million AUD | -33.72% |
| 2000 | 3.68 Million AUD | -46.58% |
| 1999 | 6.89 Million AUD | -12.65% |
| 1998 | 7.89 Million AUD | -9.23% |
| 1997 | 8.69 Million AUD | -6.01% |
| 1996 | 9.24 Million AUD | -22.45% |
| 1995 | 11.92 Million AUD | 5.42% |
| 1994 | 11.31 Million AUD | 98.54% |
| 1993 | 5.69 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 230.42 Million AUD | 0.0% |
| 2024 Q4 | 151.39 Million AUD | 0.0% |
| 2024 FY | 151.39 Million AUD | -23.17% |
| 2024 Q1 | 230.42 Million AUD | 56.11% |
| 2023 Q1 | 212.54 Million AUD | 43.99% |
| 2023 Q4 | 147.6 Million AUD | -25.1% |
| 2023 FY | 197.06 Million AUD | 33.51% |
| 2023 Q3 | 197.06 Million AUD | -7.28% |
| 2023 Q2 | 212.54 Million AUD | 0.0% |
| 2022 Q3 | 147.6 Million AUD | -7.43% |
| 2022 FY | 147.6 Million AUD | 105.55% |
| 2022 Q1 | 159.45 Million AUD | 122.05% |
| 2022 Q2 | 159.45 Million AUD | 0.0% |
| 2022 Q4 | 147.6 Million AUD | 0.0% |
| 2021 Q1 | 67.81 Million AUD | 4.01% |
| 2021 Q4 | 71.8 Million AUD | 0.0% |
| 2021 FY | 71.8 Million AUD | 10.13% |
| 2021 Q2 | 67.81 Million AUD | 0.0% |
| 2021 Q3 | 71.8 Million AUD | 5.88% |
| 2020 Q3 | 65.2 Million AUD | -7.73% |
| 2020 FY | 65.2 Million AUD | 111.85% |
| 2020 Q1 | 70.66 Million AUD | 129.59% |
| 2020 Q2 | 70.66 Million AUD | 0.0% |
| 2020 Q4 | 65.2 Million AUD | 0.0% |
| 2019 Q2 | 33.61 Million AUD | 0.0% |
| 2019 FY | 30.77 Million AUD | 81.97% |
| 2019 Q1 | 33.61 Million AUD | 98.74% |
| 2019 Q4 | 30.77 Million AUD | 0.0% |
| 2019 Q3 | 30.77 Million AUD | -8.44% |
| 2018 Q1 | 19.45 Million AUD | 53.48% |
| 2018 FY | 16.91 Million AUD | 33.42% |
| 2018 Q4 | 16.91 Million AUD | 0.0% |
| 2018 Q3 | 16.91 Million AUD | -13.07% |
| 2018 Q2 | 19.45 Million AUD | 0.0% |
| 2017 Q2 | 11.27 Million AUD | 0.0% |
| 2017 Q4 | 12.67 Million AUD | 0.0% |
| 2017 Q3 | 12.67 Million AUD | 12.46% |
| 2017 FY | 12.67 Million AUD | 32.95% |
| 2017 Q1 | 11.27 Million AUD | 18.22% |
| 2016 Q1 | 10.81 Million AUD | 18.71% |
| 2016 Q2 | 10.81 Million AUD | 0.0% |
| 2016 Q4 | 9.53 Million AUD | 0.0% |
| 2016 FY | 9.53 Million AUD | 4.62% |
| 2016 Q3 | 9.53 Million AUD | -11.87% |
| 2015 Q1 | 10.55 Million AUD | 22.26% |
| 2015 Q4 | 9.11 Million AUD | 0.0% |
| 2015 Q3 | 9.11 Million AUD | -13.63% |
| 2015 FY | 9.11 Million AUD | 5.6% |
| 2015 Q2 | 10.55 Million AUD | 0.0% |
| 2014 Q3 | 8.63 Million AUD | -12.96% |
| 2014 FY | 8.63 Million AUD | 233.97% |
| 2014 Q1 | 9.91 Million AUD | 283.71% |
| 2014 Q2 | 9.91 Million AUD | 0.0% |
| 2014 Q4 | 8.63 Million AUD | 0.0% |
| 2013 Q3 | 2.58 Million AUD | 0.0% |
| 2013 FY | 2.58 Million AUD | 96.03% |
| 2013 Q4 | 2.58 Million AUD | 0.0% |
| 2012 Q4 | 1.31 Million AUD | 0.0% |
| 2012 FY | 1.31 Million AUD | -71.87% |
| 2011 Q4 | 4.68 Million AUD | 0.0% |
| 2011 FY | 4.68 Million AUD | 14.36% |
| 2010 FY | 4.09 Million AUD | -28.88% |
| 2010 Q4 | 4.09 Million AUD | 0.0% |
| 2009 Q4 | 5.76 Million AUD | 0.0% |
| 2009 FY | 5.76 Million AUD | 11.61% |
| 2008 Q4 | 5.16 Million AUD | 0.0% |
| 2008 FY | 5.16 Million AUD | -1.84% |
| 2007 Q4 | 5.26 Million AUD | 0.0% |
| 2007 FY | 5.26 Million AUD | -27.63% |
| 2006 Q4 | 7.26 Million AUD | 0.0% |
| 2006 FY | 7.26 Million AUD | -19.81% |
| 2005 FY | 9.06 Million AUD | 50.67% |
| 2005 Q4 | 9.06 Million AUD | 0.0% |
| 2004 FY | 6.01 Million AUD | -26.13% |
| 2004 Q4 | 6.01 Million AUD | 0.0% |
| 2003 Q4 | 8.14 Million AUD | 0.0% |
| 2003 FY | 8.14 Million AUD | 864.49% |
| 2002 FY | 844.39 Thousand AUD | -65.4% |
| 2002 Q4 | 844.39 Thousand AUD | 0.0% |
| 2001 FY | 2.44 Million AUD | -33.72% |
| 2001 Q4 | 2.44 Million AUD | 0.0% |
| 2000 Q4 | 3.68 Million AUD | 0.0% |
| 2000 FY | 3.68 Million AUD | -46.58% |
| 1999 Q4 | 6.89 Million AUD | 0.0% |
| 1999 FY | 6.89 Million AUD | -12.65% |
| 1998 FY | 7.89 Million AUD | -9.23% |
| 1997 Q4 | 8.69 Million AUD | 0.0% |
| 1997 FY | 8.69 Million AUD | -6.01% |
| 1996 FY | 9.24 Million AUD | -22.45% |
| 1995 FY | 11.92 Million AUD | 5.42% |
| 1994 FY | 11.31 Million AUD | 98.54% |
| 1993 FY | 5.69 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -109897.106% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -289.728% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -198184.068% |
| SQZ Biotechnologies Company | 107.18 Million USD | -41.246% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -10472.237% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -1334.507% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -16.271% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -209114.146% |
| Marizyme, Inc. | 22.01 Million USD | -587.701% |
| Genus plc | 1.02 Billion USD | 85.285% |
| Pharming Group N.V. | 462.85 Million USD | 67.29% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -4469.794% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -30237.873% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -24046.382% |
| ContraFect Corporation | 20.67 Million USD | -632.133% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -39514.581% |
| IMV Inc. | 31.33 Million USD | -383.178% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -3551.64% |
| ONE Bio Corp. | 70.08 Million USD | -116.019% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -17.81% |
| Mesoblast Limited | 667.9 Million USD | 77.332% |
| MultiCell Technologies, Inc. | 126.22 USD | -119947465.362% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -330.364% |
| Genscript Biotech Corporation | 3.38 Billion USD | 95.529% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -19545.623% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -57845.329% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -1996.992% |
| Biomind Labs Inc. | 73.81 Thousand USD | -204993.292% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -10349.567% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -404.408% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1167.945% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -11045.69% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -5412.722% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -38683.556% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -7631.522% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -21921.949% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -16011.481% |
| EV Biologics, Inc. | 431.71 Thousand USD | -34969.008% |
| Q BioMed Inc. | 3.51 Million USD | -4206.559% |
| GB Sciences, Inc. | 103.44 Thousand USD | -146260.102% |
| Alpha Cognition Inc. | 2.45 Million USD | -6074.034% |
| CSL Limited | 38.02 Billion USD | 99.602% |
| Agentix Corp. | 261.39 Thousand USD | -57819.836% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 66.078% |
| Enzolytics Inc. | 361.7 Million USD | 58.143% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -1765.654% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -7962.167% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -5715.844% |
| argenx SE | 4.54 Billion USD | 96.667% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -441.79% |
| HST Global, Inc. | 1526.00 USD | -9921119.987% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -217.383% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -15224.178% |
| Halberd Corporation | 10.13 Thousand USD | -1494301.51% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -23568.631% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -1591.755% |
| Zenith Capital Corp. | 7410.00 USD | -2043055.425% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -664479.329% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -46946.3% |
| AVAX Technologies, Inc. | 7.37 Million USD | -1952.252% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -57826.041% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -16215.106% |
| Ember Therapeutics, Inc. | 184.00 USD | -82281322.283% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -243117.159% |
| Helix BioMedix, Inc. | 3.02 Million USD | -4904.744% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -187.277% |
| Kadimastem Ltd | 2.3 Million USD | -6470.858% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -939.799% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -265072.903% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -6553918.052% |
| LadRx Corporation | 2.3 Million USD | -6460.033% |
| Cell Source, Inc. | 195.17 Thousand USD | -77471.882% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -31404.653% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -42714.066% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -42714.066% |
| Affymax, Inc. | 7.44 Million USD | -1934.097% |
| Mobile Lads Corp. | 52.00 USD | -291149548.077% |
| Itoco Inc. | 1.4 Million USD | -10713.574% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -158171.55% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -142728.129% |
| International Stem Cell Corporation | 5.39 Million USD | -2708.865% |
| CytoDyn Inc. | 11.13 Million USD | -1259.535% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -105793.334% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -846643.943% |
| Qrons Inc. | 420.00 USD | -36046999.286% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -39176.059% |
| SYBLEU INC | 330.46 Thousand USD | -45713.155% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -27321.18% |
| Rebus Holdings, Inc. | 5000.00 USD | -3027856.34% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -36878.427% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -909.196% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -813.19% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -191542.806% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -17409.176% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -1914.072% |
| Neutra Corp. | 2851.00 USD | -5310240.828% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -367.191% |
| PureTech Health plc | 693.97 Million USD | 78.184% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -1775.804% |
| IXICO plc | 15.84 Million USD | -855.559% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -1728.034% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -46.527% |
| CSL Limited | 38.02 Billion USD | 99.602% |
| Cellectis S.A. | 333.99 Million USD | 54.671% |